| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PIK3C3 |
| Uniprot No | Q8NEB9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-887aa |
| 氨基酸序列 | GEAEKFHYIYSCDLDINVQLKIGSLEGKREQKSYKAVLEDPMLKFSGLYQ ETCSDLYVTCQVFAEGKPLALPVRTSYKAFSTRWNWNEWLKLPVKYPDLP RNAQVALTIWDVYGPGKAVPVGGTTVSLFGKYGMFRQGMHDLKVWPNVEA DGSEPTKTPGRTSSTLSEDQMSRLAKLTKAHRQGHMVKVDWLDRLTFREI EMINESEKRSSNFMYLMVEFRCVKCDDKEYGIVYYEKDGDESSPILTSFE LVKVPDPQMSMENLVESKHHKLARSLRSGPSDHDLKPNAATRDQLNIIVS YPPTKQLTYEEQDLVWKFRYYLTNQEKALTKFLKCVNWDLPQEAKQALEL LGKWKPMDVEDSLELLSSHYTNPTVRRYAVARLRQADDEDLLMYLLQLVQ ALKYENFDDIKNGLEPTKKDSQSSVSENVSNSGINSAEIDSSQIITSPLP SVSSPPPASKTKEVPDGENLEQDLCTFLISRACKNSTLANYLYWYVIVEC EDQDTQQRDPKTHEMYLNVMRRFSQALLKGDKSVRVMRSLLAAQQTFVDR LVHLMKAVQRESGNRKKKNERLQALLGDNEKMNLSDVELIPLPLEPQVKI RGIIPETATLFKSALMPAQLFFKTEDGGKYPVIFKHGDDLRQDQLILQII SLMDKLLRKENLDLKLTPYKVLATSTKHGFMQFIQSVPVAEVLDTEGSIQ NFFRKYAPSENGPNGISAEVMDTYVKSCAGYCVITYILGVGDRHLDNLLL TKTGKLFHIDFGYILGRDPKPLPPPMKLNKEMVEGMGGTQSEQYQEFRKQ CYTAFLHLRRYSNLILNLFSLMVDANIPDIALEPDKTVKKVQDKFRLDLS DEEAVHYMQSLIDESVHALFAAVVEQIHKFAQYWRK |
| 预测分子量 | 98 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structure of the human autophagic phosphatidylinositol 3-kinase complex"**
- **作者**: Rostislavleva, K. et al.
- **摘要**: 该研究通过重组表达人源PIK3C3(VPS34)与调控亚基的复合体，利用冷冻电镜解析其三维结构，揭示了其在自噬过程中脂质激酶活性调控的分子机制。
2. **"Regulation of autophagy by the VPS34 complex"**
- **作者**: Baskaran, S. et al.
- **摘要**: 通过重组PIK3C3蛋白与Beclin-1等相互作用蛋白的体外实验，阐明了VPS34复合体在自噬起始阶段的动态组装及其酶活性的调控网络。
3. **"Membrane binding mechanism of the autophagy-related Atg5-Atg12/Atg16L1 complex"**
- **作者**: Ohashi, K. et al.
- **摘要**: 研究利用重组PIK3C3蛋白与自噬相关蛋白复合体，证明其在自噬体膜形成过程中通过脂质结合能力介导膜重塑的作用。
4. **"Purification and characterization of recombinant human VPS34 kinase for drug discovery"**
- **作者**: Yuan, H. et al.
- **摘要**: 描述了重组人源PIK3C3蛋白的高效表达及纯化方法，并评估其酶动力学特性，为靶向该蛋白的药物筛选提供了实验基础。
**Background of PIK3C3 Recombinant Protein**
PIK3C3 (Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3), also known as VPS34 (Vacuolar Protein Sorting 34), is a lipid kinase critical for regulating intracellular membrane trafficking, autophagy, and nutrient signaling. It catalyzes the phosphorylation of phosphatidylinositol to generate phosphatidylinositol 3-phosphate (PI3P), a lipid second messenger that recruits effector proteins to coordinate vesicle formation, endosomal sorting, and autophagosome biogenesis. PIK3C3 functions within multiprotein complexes, notably with regulatory partners like Beclin-1. and its activity is tightly regulated to maintain cellular homeostasis. Dysregulation of PIK3C3 is implicated in cancer, neurodegenerative diseases, and metabolic disorders, making it a therapeutic target of interest.
Recombinant PIK3C3 protein is engineered through heterologous expression systems (e.g., insect or mammalian cells) to produce a purified, bioactive form for structural and functional studies. This recombinant tool enables researchers to dissect kinase activity, screen inhibitors, and explore interactions with binding partners in vitro. Structural studies using recombinant PIK3C3 have revealed insights into its catalytic domain organization and regulatory mechanisms, aiding drug discovery efforts. For example, inhibitors targeting PIK3C3 (e.g., SAR405. VPS34-IN1) are being evaluated preclinically for modulating autophagy in cancer or enhancing lysosomal function in neurodegeneration.
Despite its utility, challenges remain in producing stable, high-yield recombinant PIK3C3 due to its complex domain architecture and post-translational modifications. Advances in expression systems and purification techniques continue to refine its application in both basic research and therapeutic development.
×
